Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$4.07 USD
+0.14 (3.56%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.02 -0.05 (-1.23%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Aquestive Therapeutics (AQST) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.29 | $12.00 | $7.00 | 136.39% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Aquestive Therapeutics comes to $9.29. The forecasts range from a low of $7.00 to a high of $12.00. The average price target represents an increase of 136.39% from the last closing price of $3.93.
Analyst Price Targets (7 )
Broker Rating
Aquestive Therapeutics currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.17 a month ago based on six recommendations.
Of the seven recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 85.71% and 14.29% of all recommendations. A month ago, Strong Buy made up 83.33%, while Buy represented 16.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 5 | 4 | 4 |
Buy | 1 | 1 | 1 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.14 | 1.14 | 1.17 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/11/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
3/28/2024 | Raymond James | Gary Nachman | Moderate Buy | Moderate Buy |
3/15/2024 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
3/8/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
3/7/2024 | Lake Street Capital Markets | Thomas Flaten | Not Available | Strong Buy |
3/6/2024 | Wedbush Securities | Andreas Argyrides | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.14 |
ABR (Last week) | 1.14 |
# of Recs in ABR | 7 |
Average Target Price | $9.29 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.09 |